SCHEMBL6138510

SCHEMBL6138510

CN(C)Cc1ccc(-c2ccc([C@@H](O)CCCCC(=O)NO)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 12/20 0.50
HDAC8 Q9BY41 6/20 0.50
HDAC2 Q92769 7/20 0.47
HRH3 Q9Y5N1 1/20 0.44
HDAC6 Q9UBN7 8/20 0.43
HDAC3 O15379 6/20 0.43
NCOR2 Q9Y618 2/20 0.43
HDAC4 P56524 3/20 0.42
HDAC7 Q8WUI4 3/20 0.42
HDAC10 Q969S8 3/20 0.42
HDAC11 Q96DB2 3/20 0.42
HDAC9 Q9UKV0 3/20 0.42
HDAC5 Q9UQL6 3/20 0.42
MMP3 P08254 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138851 1.00 HDAC1 (0.50) HDAC1HDAC8HDAC2HRH3HDAC6
SCHEMBL6138517 1.00 HDAC1 (0.50) HDAC1HDAC8HDAC2HRH3HDAC6
Hydrochloric Acid SCHEMBL6138931 0.99 HDAC1 (0.49) HDAC1HDAC8HDAC2HRH3HDAC6
Hydrochloric Acid SCHEMBL6138939 0.99 HDAC1 (0.49) HDAC1HDAC8HDAC2HRH3HDAC6
Hydrochloric Acid SCHEMBL6138946 0.99 HDAC1 (0.49) HDAC1HDAC8HDAC2HRH3HDAC6
SCHEMBL6138934 0.88 HDAC2 (0.51) HDAC1HDAC8HDAC2HRH3HDAC6
SCHEMBL6139137 0.88 HDAC2 (0.51) HDAC1HDAC8HDAC2HRH3HDAC6
Hydrochloric Acid SCHEMBL6138884 0.86 HDAC2 (0.50) HDAC1HDAC8HDAC2HRH3HDAC6
Hydrochloric Acid SCHEMBL6138888 0.86 HDAC2 (0.50) HDAC1HDAC8HDAC2HRH3HDAC6
SCHEMBL6138877 0.85 HRH3 (0.49) HDAC1HDAC8HDAC2HRH3HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP claimed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US claimed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient HIF1AN, IL6, PYGM HDAC1 942/4885HDAC8 1134/4885HDAC2 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.